Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc.’s Chief Development Officer Darlene Noci exercised stock options and sold shares of Class A Common Stock. On July 1, 2026, she exercised options for a total of 23,000 shares at exercise prices of $72.35 and $18.93 per share, then sold 23,000 shares in an open-market transaction at a weighted average price of $123.59 per share. After these transactions, she directly owned 58,117 shares of Class A Common Stock. The filing notes the transactions were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom exercised stock options and sold shares of Class A Common Stock. She exercised options to acquire 6,046 shares at $18.93 per share and 5,384 shares at $6.89 per share, then sold 11,430 shares in an open-market transaction at a weighted average price of $123.58 per share. These trades were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, she directly holds 85,533 shares of Class A Common Stock and retains stock options covering 22,933 and 8,016 shares with exercise prices of $18.93 and $6.89, respectively.
NUVL submitted a Form 144 notice reporting a proposed sale of Class A Common shares via NQ Stock Options, with the listed method as Cash and an entry date of 07/01/2026. The excerpt also lists multiple sales attributed to Alexandra Balcom, including 11,430 shares on 03/24/2026 (1,094,401), 13,700 shares on 03/25/2026 (1,372,158), 11,430 shares on 04/01/2026 (1,202,555), 11,430 shares on 05/01/2026 (1,131,589), and 11,430 shares on 06/01/2026 (1,128,083). The filing lists J.P. Morgan Securities LLC as the broker of record.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported an exercise-and-sell transaction in Class A Common Stock. She exercised stock options to acquire 5,500 shares at $27.85 per share and sold 5,500 shares in open-market trades at a weighted average price of $123.51 per share.
The filing shows these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. After the sale, she directly held 58,117 shares of Nuvalent Class A Common Stock.
Nuvalent, Inc. is the subject of a cash tender offer by Harmony Row Acquisition Co., GlaxoSmithKline LLC and GSK plc to purchase all outstanding Class A and Class B shares for $124.00 per share. The Offer to Purchase and accompanying Letter of Transmittal dated June 24, 2026 set the terms and conditions, and the Schedule TO has been amended to add a press release by Ultimate Parent filed as Exhibit (a)(5)(K). The Offer Price is net to sellers in cash, subject to withholding taxes and the conditions in the Merger Agreement and Offer materials.
Nuvalent, Inc. recommends that holders accept the cash tender offer by Harmony Row Acquisition Co., an indirect acquisition vehicle of GSK plc, which offers $124.00 per Share in cash. The Offer will expire at one minute after 11:59 p.m. ET on July 14, 2026, subject to extension and customary conditions, including minimum tender and HSR clearance.
The Schedule 14D-9 describes that the Merger will occur under a merger agreement dated June 9, 2026, and that outstanding stock options, RSUs and PSUs will be cancelled for cash payments calculated using the Offer Price. The Board unanimously determined the Transactions are advisable and recommends tendering.
GSK plc, GlaxoSmithKline LLC and Harmony Row Acquisition Co. are offering to purchase all issued and outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share in cash, subject to the terms and conditions set forth in the Offer to Purchase and the Agreement and Plan of Merger. The Offer Price may be increased pursuant to the Merger Agreement.
As context, the Company reported 73,899,592 Class A Shares and 5,435,254 Class B Shares issued and outstanding as of June 17, 2026. The Schedule TO incorporates the Offer to Purchase, Letter of Transmittal and related exhibits, including the Merger Agreement dated June 9, 2026 and a Facility Agreement among financing parties.
Flynn James E reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. reported an updated insider position for entities affiliated with Deerfield Management Company, L.P., highlighting a new equity award tied to board service. On June 16, 2026, 3,444 restricted stock units (RSUs) were granted to director Cameron Wheeler, which are held for the benefit and at the direction of Deerfield Management.
Each RSU represents one share of Nuvalent Class A common stock and vests in full on the earlier of June 16, 2027 or the company’s next annual stockholder meeting, subject to Wheeler’s continued service. The filing also lists indirect Class A common stock holdings through several Deerfield funds, including 8,299,225 shares through Deerfield Healthcare Innovations Fund, L.P., 650,000 shares through Deerfield Partners, L.P., and 10,292 shares through Deerfield Management Company, L.P. The reporting persons disclaim beneficial ownership except to the extent of any indirect pecuniary interest.
Wheeler Cameron reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. reported that 3,444 shares of its Class A Common Stock were awarded in the form of restricted stock units to director Cameron Wheeler. The award was granted at no cash cost per share and brings the reported holding to 8,590 RSUs.
According to the disclosure, Wheeler is a partner in Deerfield Management Company, L.P., has no pecuniary interest in these securities, and holds them for the benefit and at the direction of Deerfield. The RSUs vest in full on the earlier of June 16, 2027 or Nuvalent’s next annual stockholder meeting, subject to continued service.
Srivastava Sapna reported acquisition or exercise transactions in this Form 4 filing.
Nuvalent, Inc. director Sapna Srivastava received an equity award of 3,444 restricted stock units (RSUs) of Class A Common Stock. Each RSU represents the right to receive one share of Nuvalent Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the company’s next annual meeting of stockholders, subject to her continued service. Following this grant, she holds 8,590 shares of Class A Common Stock directly.